Your browser doesn't support javascript.
loading
Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.
Wright, David; Rodriguez, Allen; Godofsky, Eliot; Walmsley, Sharon; Labriola-Tompkins, Emily; Donatacci, Lucille; Shikhman, Anna; Tucker, Ernestine; Chiu, Yu-Yuan; Chung, Jain; Rowell, Lucy; Demasi, Ralph; Graham, Neil; Salgo, Miklos.
Affiliation
  • Wright D; Central Texas Clinical Research LLC, Austin, Texas 78705, USA. dwight@seton.org
HIV Clin Trials ; 9(2): 73-82, 2008.
Article in En | MEDLINE | ID: mdl-18474492
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Peptide Fragments / HIV Envelope Protein gp41 / HIV Infections / HIV Fusion Inhibitors Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: HIV Clin Trials Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) / TERAPEUTICA Year: 2008 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Peptide Fragments / HIV Envelope Protein gp41 / HIV Infections / HIV Fusion Inhibitors Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: HIV Clin Trials Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) / TERAPEUTICA Year: 2008 Type: Article Affiliation country: United States